In recent years, adeno-associated virus (AAV) has become the most important vector for
central nervous system (CNS) gene therapy. AAV has already shown promising results in …

Current processes for the production of recombinant adeno-associated virus (rAAV) are
inadequate to meet the surging demand for rAAV-based gene therapies. This article reviews …

Adeno-associated viruses (AAVs) demand for clinical trials and approved therapeutic
applications is increasing due to this vector's overall success and potential. The high doses …

Gene therapy aims to add, replace or turn off genes to help treat disease. To date, the US
Food and Drug Administration (FDA) has approved 14 gene therapy products. With the …

The majority of recombinant adeno‐associated viruses (rAAV) approved for clinical use or in
clinical trials areproduced by transient transfection using the HEK293 cell line. However, this …

In current manufacturing processes for recombinant adeno-associated viral vectors (rAAV),
endonuclease treatment is used prior to depth filtration to break down host cell DNA that is …

Virus-based biopharmaceutical products are used in clinical applications such as vaccines,
gene therapy, and immunotherapy. However, their manufacturing remains a challenge …

8. Newby, GA, Yen, JS, Woodard, KJ, Mayuranathan, T., Lazzarotto, CR, Li, Y., Sheppard-
Tillman, H., Porter, SN, Yao, Y., Mayberry, K., et al.(2021). Base editing of haematopoietic …

Recombinant adeno-associated virus (rAAV) is one of the most widely used viral vectors that
has been used for gene therapy to treat a variety of human diseases. As a newly developed …

Viral vectors are an emerging, exciting class of biologics whose application in vaccines,
oncology, and gene therapy has grown exponentially in recent years. Following first …